The EPHOS-B Trial met one of its primary objectives, that 11 days of anti-HER2 therapy, between diagnosis and surgery, without chemotherapy, reduced proliferation, which was seen in all active treatment groups but particularly with the dual-agent combination where a Ki67 decrease greater than 30% was seen in 74% of cancers. Here, ERBB2 is linked to cancer.